Eargo (EAR) Debt-to-Equity : 0.17 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Eargo Debt-to-Equity?

Eargo's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.62 Mil. Eargo's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $7.03 Mil. Eargo's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $45.13 Mil. Eargo's debt to equity for the quarter that ended in Sep. 2023 was 0.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eargo's Debt-to-Equity or its related term are showing as below:

EAR' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.63 Med: 0.09 Max: 9.52
Current: 0.17

During the past 6 years, the highest Debt-to-Equity Ratio of Eargo was 9.52. The lowest was -3.63. And the median was 0.09.

EAR's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs EAR: 0.17

Eargo Debt-to-Equity Historical Data

The historical data trend for Eargo's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eargo Debt-to-Equity Chart

Eargo Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-0.06

-0.08

0.08

0.33

0.07

Eargo Quarterly Data
	Dec17	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															-3.63	0.07	0.10	0.13	0.17

Competitive Comparison of Eargo's Debt-to-Equity

For the Medical Devices subindustry, Eargo's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eargo's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eargo's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eargo's Debt-to-Equity falls into.

Eargo Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eargo's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.628	+	5.973)	/	100.854
	=	0.07

Eargo's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.624	+	7.03)	/	45.129
	=	0.17

Eargo (NAS:EAR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eargo Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eargo's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eargo (EAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eargo Inc (NAS:EAR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2665 North First Street, Suite 300, San Jose, CA, USA, 95134

Website

https://www.eargo.com

Eargo Inc is a medical device company, focused on improving the quality of life of people with hearing loss. The company offers hearing aids, professional support services, and other insurance-related services through a direct-to-consumer format with a personalized, consumer-centric approach. The product portfolio includes Eargo Neo HiFi, Eargo 5, Eargo 6, Eargo 7, and related accessories.

Executives

Mark Thorpe	officer: Chief Accounting Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William Brownie	officer: Chief Operating Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Adam Laponis	officer: Chief Financial Officer	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Christian Gormsen	director, officer: President and CEO	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Trit Garg	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Afshin Justin Sabet-peyman	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Onkarr Narula	director	C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Donald J Spence	director	C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Psc Echo Gp, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Psc Echo, Lp	10 percent owner	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
David James Wu	director	411 FIRST AVENUE SOUTH, SUITE 600, SEATTLE WA 98104
Nina Richardson	director	C/O SILICON LABORATORIES, 400 W CESAR CHAVEZ, AUSTIN TX 78701
Katie J Bayne	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Geoff Pardo	director	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Gilde Healthcare Holding B.v.	10 percent owner	NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB